articleThe LancetFeb 1, 2023Closed access

Tenecteplase versus alteplase in acute ischaemic cerebrovascular events (TRACE-2): a phase 3, multicentre, open-label, randomised controlled, non-inferiority trial

YWYongjun WangYWYongjun WangSLShuya LiYPYuesong PanHLHao Li

Capital Medical University · Beijing Tian Tan Hospital · +16 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

284
total citations
FWCI
57.94
Percentile
100%
References
25
Citations per year

Authors

75

Topics & keywords

Keywords
  • Medicine
  • Tenecteplase
  • Modified Rankin Scale
  • Thrombolysis
  • Stroke (engine)
  • Clinical endpoint
  • Fibrinolytic agent
  • Randomized controlled trial
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.